BioLargo Statistics
Total Valuation
BioLargo has a market cap or net worth of 63.21 million. The enterprise value is 61.18 million.
| Market Cap | 63.21M |
| Enterprise Value | 61.18M |
Important Dates
The next estimated earnings date is Thursday, August 14, 2025.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BioLargo has 305.37 million shares outstanding. The number of shares has increased by 3.63% in one year.
| Current Share Class | 305.37M |
| Shares Outstanding | 305.37M |
| Shares Change (YoY) | +3.63% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 6.10% |
| Owned by Institutions (%) | 0.04% |
| Float | 262.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.88 |
| PB Ratio | 12.42 |
| P/TBV Ratio | 8.31 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -19.44 |
| EV / Sales | 3.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -10.39 |
Financial Position
The company has a current ratio of 2.14, with a Debt / Equity ratio of 0.60.
| Current Ratio | 2.14 |
| Quick Ratio | 2.01 |
| Debt / Equity | 0.60 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.52 |
| Interest Coverage | -63.14 |
Financial Efficiency
Return on equity (ROE) is -107.31% and return on invested capital (ROIC) is -45.36%.
| Return on Equity (ROE) | -107.31% |
| Return on Assets (ROA) | -33.38% |
| Return on Invested Capital (ROIC) | -45.36% |
| Return on Capital Employed (ROCE) | -76.07% |
| Revenue Per Employee | 387,810 |
| Profits Per Employee | -74,929 |
| Employee Count | 44 |
| Asset Turnover | 1.60 |
| Inventory Turnover | 29.65 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -22.59% in the last 52 weeks. The beta is 0.13, so BioLargo's price volatility has been lower than the market average.
| Beta (5Y) | 0.13 |
| 52-Week Price Change | -22.59% |
| 50-Day Moving Average | 0.22 |
| 200-Day Moving Average | 0.23 |
| Relative Strength Index (RSI) | 46.20 |
| Average Volume (20 Days) | 416,613 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.08 |
Income Statement
In the last 12 months, BioLargo had revenue of 16.29 million and -3.15 million in losses. Loss per share was -0.01.
| Revenue | 16.29M |
| Gross Profit | 7.10M |
| Operating Income | -5.43M |
| Pretax Income | -5.49M |
| Net Income | -3.15M |
| EBITDA | -5.23M |
| EBIT | -5.43M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 2.56 million in cash and 3.05 million in debt, giving a net cash position of -489,000 or -0.00 per share.
| Cash & Cash Equivalents | 2.56M |
| Total Debt | 3.05M |
| Net Cash | -489,000 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | 5.09M |
| Book Value Per Share | 0.03 |
| Working Capital | 3.85M |
Cash Flow
In the last 12 months, operating cash flow was -5.52 million and capital expenditures -372,000, giving a free cash flow of -5.89 million.
| Operating Cash Flow | -5.52M |
| Capital Expenditures | -372,000 |
| Free Cash Flow | -5.89M |
| FCF Per Share | -0.02 |
Margins
Gross margin is 43.56%, with operating and profit margins of -33.34% and -19.32%.
| Gross Margin | 43.56% |
| Operating Margin | -33.34% |
| Pretax Margin | -33.72% |
| Profit Margin | -19.32% |
| EBITDA Margin | -32.13% |
| EBIT Margin | -33.34% |
| FCF Margin | n/a |
Dividends & Yields
BioLargo does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.63% |
| Shareholder Yield | n/a |
| Earnings Yield | -4.98% |
| FCF Yield | -9.32% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioLargo has an Altman Z-Score of -11.2 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.2 |
| Piotroski F-Score | 1 |